slide img

To relieve patient suffering
and enhance lives

Using our novel R&D platform for the advancement of life-changing medicines, we focus on developing and commercializing treatments for neurological and endocrine related disorders.

Our Services More About Us!
slide img

is an involuntary
movement disorder

We have developed the first FDA-approved treatment for adults with tardive dyskinesia, an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents.

Our Services More About Us!

Quick Contact

Our Location

  • #125, Kuber Siddhi2, Atak Pardi, Valsad-396007
A Leading Developer Of A Grade Commercial & Residential Projects

Today Promin has over 4,000 professionals on its payroll All Over The World.

Learn More
background
The Best A Grade Commercial & Residential Services

High Quality Construction Solutions For Residentials & Industries!

Clinical Trials

Neurocrine Biosciences completed a Phase II study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont in adult patients with classic congenital adrenal hyperplasia (CAH).

background

Pipeline

There are currently no non-steroidal FDA-approved treatments for classic CAH. Corticosteroids, the current standard of care, are used to both correct the endogenous cortisol deficiency and reduce the excessive.

background

Webcasts & Presentation

Neurocrine Biosciences’s management team participates in industry conferences providing presentations on company updates and progress on research and development activities with proper guidance.

background

Offering high quality construction solutions. Build Your Dream Now!

Featured Projects

Our Recent Works

portfolio img

INGREZZA

INGREZZA is indicated for the treatment of adults with tardive dyskinesia. The initial dosage for INGREZZA is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. Continuation of 40 mg once daily may be considered for some patients.

portfolio img

ONGENTYS

ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. The recommended dosage of ONGENTYS is 50 mg administered orally once daily at bedtime. Patients should not eat food for 1 hour before and for at least 1 hour after intake of ONGENTYS.

client
client
client
client
client
client
client
client
background

Our Location

  • #125, Kuber siddhi2, Atak Pardi, Valsad-396007

Quick Contact

We will get back to you within 24 hours, or call us everyday, 09:00 AM - 12:00 PM
(+91) 635 442 5147

Request A Quote

Complete control over products allows us to ensure our customers receive the best quality prices and service. We take great pride in everything that we do in our factory.

What Our Clients Say!

author thumb John Peter Pharma Inc
author thumb Sami Wade Trustry
author thumb Sami Wade Trustry

They are the best and expertly trained team members who take the extra step and go the extra mile, all to fulfill our promise to deliver innovative and dynamic solutions to our customers to fit the needs of a rapidly changing global environment

All to fulfill our promise to deliver innovative and dynamic solutions to our customers to fit the needs of a rapidly changing global environment. They are the best and expertly trained team members who take the extra step and go the extra mile.

They are the best and expertly trained team members who take the extra step and go the extra mile, all to fulfill our promise to deliver innovative and dynamic solutions to our customers to fit the needs of a rapidly changing global environment.